Literature DB >> 22416788

Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer.

Firas Abdollah1, Maxine Sun, Rodolphe Thuret, Claudio Jeldres, Zhe Tian, Alberto Briganti, Shahrokh F Shariat, Paul Perrotte, Francesco Montorsi, Pierre I Karakiewicz.   

Abstract

OBJECTIVES: To test the relationship between the extent of pelvic lymph node dissection at radical prostatectomy and the rate of lymph node metastases, and to identify the ideal number of lymph nodes that should be removed to achieve an optimal staging.
METHODS: We assessed 20 789 prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection between 2004 and 2006. Receiver operating characteristics analyses were used to define the probability of correctly staging lymph node metastases patients according to lymph node count. Univariable and multivariable regression analyses tested the relationship between lymph node count and lymph node metastases rate.
RESULTS: The average lymph node count was 6.4 (median 5.0). Overall, the lymph node metastases rate was 2.5%; and it resulted to be 0.2, 1.5 and 6.7% in low, intermediate and high-risk tumors, respectively. The rate of lymph node metastases was 3.5 and 6.7% in patients with 10 and 20 lymph node count, respectively. Removing 20 lymph nodes yielded a 90% probability of correctly staging lymph node metastases, regardless of risk group. In multivariable analysis, lymph node count was an independent predictor of lymph node metastases stage (odds ratio: 1.07, P < 0.001).
CONCLUSIONS: A direct relationship might exist between the extent of pelvic lymph node dissection and the lymph node metastases rate. An extended pelvic lymph node dissection with at least 20 lymph nodes would offer correct lymph node staging in 90% of cases, regardless of tumor characteristics. This cut-off might be considered adequate by most surgeons. Such a high lymph node yield necessitates an anatomically extended pelvic lymph node dissection.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2012        PMID: 22416788     DOI: 10.1111/j.1442-2042.2012.02993.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  18 in total

1.  Current status of pelvic lymph node dissection in prostate cancer.

Authors:  Ilija Aleksic; Tyler Luthringer; Vladimir Mouraviev; David M Albala
Journal:  J Robot Surg       Date:  2013-12-11

2.  The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

Authors:  L Tosco; A Laenen; A Briganti; P Gontero; R J Karnes; M Albersen; P J Bastian; P Chlosta; F Claessens; F K Chun; W Everaerts; C Gratzke; M Graefen; B Kneitz; G Marchioro; R S Salas; B Tombal; T Van den Broeck; L Moris; A Battaglia; H van der Poel; J Walz; A Bossi; G De Meerleer; K Haustermans; H Van Poppel; M Spahn; S Joniau
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-05-09       Impact factor: 5.554

3.  Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer.

Authors:  Angelika Borkowetz; Johannes Bruendl; Martin Drerup; Jonas Herrmann; Hendrik Isbarn; Burkhard Beyer
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

4.  Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan.

Authors:  Shuichi Morizane; Masashi Honda; Satoshi Fukasawa; Atsushi Komaru; Junichi Inokuchi; Masatoshi Eto; Masaki Shimbo; Kazunori Hattori; Yoshiaki Kawano; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2017-12-11       Impact factor: 3.402

5.  Significance of examined lymph-node count in accurate staging and long-term survival in patients undergoing radical prostatectomy: a population-based study.

Authors:  Cheng Chen; Jie Shen; Zhaoyu Xing; Changchuan Jiang; Linkun Hu; Li Cui; Dong Xue; Xiaozhou He; Renfang Xu
Journal:  Int Urol Nephrol       Date:  2019-09-30       Impact factor: 2.370

6.  Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases.

Authors:  Livia Maccio; Valeria Barresi; Federica Domati; Eugenio Martorana; Anna Maria Cesinaro; Mario Migaldi; Francesco Iachetta; Antonio Ieni; Luca Reggiani Bonetti
Journal:  Intern Emerg Med       Date:  2016-02-13       Impact factor: 3.397

Review 7.  Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.

Authors:  Michele Colicchia; Vidit Sharma; Firas Abdollah; Alberto Briganti; R Jeffrey Karnes
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

8.  Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer.

Authors:  Yohei Shida; Tomoaki Hakariya; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasuyoshi Miyata; Hideki Sakai
Journal:  Cancer Diagn Progn       Date:  2022-01-03

9.  Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.

Authors:  Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh
Journal:  Urology       Date:  2013-09       Impact factor: 2.649

10.  Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.

Authors:  Steven N Seyedin; Darrion L Mitchell; Sarah L Mott; J Kyle Russo; Chad R Tracy; Anthony N Snow; Jessica R Parkhurst; Mark C Smith; John M Buatti; John M Watkins
Journal:  Pathol Oncol Res       Date:  2017-10-27       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.